Thawing and infusion of CAR-T cell products
DOI:
https://doi.org/10.46765/2675-374X.2022v3n1p165Keywords:
CAR-T cells; thawing; infusion.Abstract
Some patients with hematologic malignancies may benefit from chimeric antigen receptor-T (CAR-T) cell treatment. Usually, the manufacture of this cells is carried out by centralized and specialized cell therapy laboratories that cryopreserve the CAR-T cells in bags and send it for infusion in the patient treatment center. In this context, the thawing and infusion of the CAR-T cell products are critical steps in this custody chain. This article aims to discuss the most relevant points related with the CAR-T cell thawing and infusion and proposes a kind of standard operational protocol (SOP) for these processes.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.